AIMS: The aim of this study was to evaluate the role of IL-6 point-of-care test in amniotic fluid obtained from serial amniocentesis in expectantly managed women with PPROM between 24 and 34 weeks of gestation. METHODS: We conducted a prospective observational cohort study which included 62 pregnant women with PPROM in gestational weeks between 22+0 and 34+0. Women aged >18 years were eligible if they presented with PPROM and a singleton pregnancy. Only women who delivered at >24.0 weeks were included in the study. In all women, the maternal blood sampling and a transabdominal amniocentesis were performed at the time of admission prior to the administration of corticosteroids, antibiotics, or tocolytics, to rule out signs of chorioamnionitis. Maternal temperature, maternal serum C-reactive protein (CRP) and white blood cell (WBC) counts were assayed every subsequent day until delivery. Amniotic fluid was used for the clinical assessment (IL-6 point-of-care test, identification of microorganisms in the amniotic fluid. After one week of expectant management of PPROM, second amniocentesis with amniotic fluid sampling was performed in patients who did not deliver. For all newborns, medical records regarding neonatal morbidity and mortality were reviewed. RESULTS: In total, 62 women aged 19 to 41 years were recruited in the study. The mean gestational age at the time of PPROM was 31+0, the mean gestational age at labor was 32+1, and the median time from PPROM to childbirth was 112 h. IL-6 point-of-care test values above 1,000 pg/mL (positive Il-6 AMC) were found in 12 women (19.4%) with median interval from PPROM to childbirth 56 h (min-max: 6.4-288). IL-6 point-of-care test values below 1,000 pg/mL (negative Il-6 AMC) were found in 51 women (81.0%). The neonatal mortality rate was 1.9% and was associated with prematurity. CONCLUSION: The major clinical finding of our study is that serial transabdominal amniocentesis with Il-6 point-of-care test helps to identify a high inflammatory status in amniotic fluid in women with PPROM. Subsequent expectant management of women with PPROM does not lead to worsening of short-term neonatal outcomes.

Department of Medical Biophysics Faculty of Medicine and Dentistry Palacky University Olomouc Hnevotinska 3 779 00 Olomouc Czech Republic

Department of Neonatology Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc 1 P Pavlova 6 775 20 Olomouc Czech Republic

Department of Obstetrics and Gynecology Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc 1 P Pavlova 6 775 20 Olomouc Czech Republic

Literatura

000      

00000naa a2200000 a 4500

001      

bmc22005981

003      

CZ-PrNML

005      

20220228153124.0

007      

ta

008      

220207s2021 xr d f 000 0|eng||

009      

AR

024    7_

$a 10.5507/bp.2020.041 $2 doi

035    __

$a (PubMed)33087938

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xr

100    1_

$a Fulová, Veronika $7 xx0269812 $u Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic

245    10

$a Transabdominal amniocentesis in expectant management of preterm premature rupture of membranes: A single center prospective study / $c V. Fulova, E. Hostinska, M. Studnickova, K. Huml, J. Zapletalova, J. Halek, R. Pilka

504    __

$a Literatura

520    9_

$a AIMS: The aim of this study was to evaluate the role of IL-6 point-of-care test in amniotic fluid obtained from serial amniocentesis in expectantly managed women with PPROM between 24 and 34 weeks of gestation. METHODS: We conducted a prospective observational cohort study which included 62 pregnant women with PPROM in gestational weeks between 22+0 and 34+0. Women aged >18 years were eligible if they presented with PPROM and a singleton pregnancy. Only women who delivered at >24.0 weeks were included in the study. In all women, the maternal blood sampling and a transabdominal amniocentesis were performed at the time of admission prior to the administration of corticosteroids, antibiotics, or tocolytics, to rule out signs of chorioamnionitis. Maternal temperature, maternal serum C-reactive protein (CRP) and white blood cell (WBC) counts were assayed every subsequent day until delivery. Amniotic fluid was used for the clinical assessment (IL-6 point-of-care test, identification of microorganisms in the amniotic fluid. After one week of expectant management of PPROM, second amniocentesis with amniotic fluid sampling was performed in patients who did not deliver. For all newborns, medical records regarding neonatal morbidity and mortality were reviewed. RESULTS: In total, 62 women aged 19 to 41 years were recruited in the study. The mean gestational age at the time of PPROM was 31+0, the mean gestational age at labor was 32+1, and the median time from PPROM to childbirth was 112 h. IL-6 point-of-care test values above 1,000 pg/mL (positive Il-6 AMC) were found in 12 women (19.4%) with median interval from PPROM to childbirth 56 h (min-max: 6.4-288). IL-6 point-of-care test values below 1,000 pg/mL (negative Il-6 AMC) were found in 51 women (81.0%). The neonatal mortality rate was 1.9% and was associated with prematurity. CONCLUSION: The major clinical finding of our study is that serial transabdominal amniocentesis with Il-6 point-of-care test helps to identify a high inflammatory status in amniotic fluid in women with PPROM. Subsequent expectant management of women with PPROM does not lead to worsening of short-term neonatal outcomes.

650    12

$a amniocentéza $7 D000649

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a předčasný odtok plodové vody $7 D005322

650    _2

$a lidé $7 D006801

650    12

$a interleukin-6 $7 D015850

650    _2

$a těhotenství $7 D011247

650    _2

$a prospektivní studie $7 D011446

650    _2

$a pozorné vyčkávání $7 D057832

655    _2

$a časopisecké články $7 D016428

655    _2

$a pozorovací studie $7 D064888

700    1_

$a Hostinská, Eliška $7 xx0243345 $u Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic

700    1_

$a Studničková, Martina $7 xx0143719 $u Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic

700    1_

$a Huml, Karel $7 xx0228057 $u Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic

700    1_

$a Zapletalová, Jana $7 xx0111614 $u Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic

700    1_

$a Hálek, Jan $7 xx0096864 $u Department of Neonatology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic

700    1_

$a Pilka, Radovan, $d 1964- $7 xx0042227

773    0_

$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 165, č. 3 (2021), s. 305-315

856    41

$u https://pubmed.ncbi.nlm.nih.gov/33087938 $y Pubmed

910    __

$a ABA008 $b A 1502 $c A 1502 $y p $z 0

990    __

$a 20220207 $b ABA008

991    __

$a 20220228153122 $b ABA008

999    __

$a ok $b bmc $g 1763631 $s 1157134

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 165 $c 3 $d 305-315 $e 20201001 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606

LZP    __

$b NLK118 $a Pubmed-20220207